ACEP call for abstracts
- Publisher
- Elsevier Science
- Year
- 1991
- Tongue
- English
- Weight
- 136 KB
- Volume
- 20
- Category
- Article
- ISSN
- 1097-6760
No coin nor oath required. For personal study only.
โฆ Synopsis
INDICATIONS AND USAGE
DURICEF ยฎ (cefadrexil monchydrate) is indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms:
Udnary tract infections caused by E. coil, P. mirabilis, and Kleb$iella species. Skin and skin structure infections caused by staphylococci and/or streptococci. Pharyngitis and tonsillitis caused by group A beta-hemolytic streptococci. (Penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. DURICEF is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of DURICEF in the subsequent prevention of rheumatic fever are not available at present.) Note: Culture and susceplibitity tests should be initiated pdor to and during therapy. Renal function studies should be performed when indicated. CONTRAINDICATIONS DURICEF is contraindicated in patients with known allergy to the cephalosporin group of antibiotics.
๐ SIMILAR VOLUMES
Oigtbmd is a stone, lyopNllzed powder of anhgen bmdmg fragments (Fab) denved from specific anhdtgox-[n antibodies raised In sheep CONTRAINDICATIONS: None known WARNINGS: Sutctdal Ingestion often involves mere than one drug and thts posstblhty must be constdered Anaphylachc, hypersensdtvity, or febri
~arcailll~ HCl (bupivacaine HCI injection, USP) ;' o' , ~e~;~:i ~2Vl ~oo. ooo Carcinogenesis, Mutagenesis, and Impairment of Fertility: Long-term studies in animals of most local anesthetics including bupivecaine have not been conducted. There is no evidence from human data that MARCAINE may be carc
The following is a brief summary only. Before prescribing, see comglste prescribing information in Pedla-Proferl [abegng. INDICATIONS AND USAGE: Pedla-Prolen is indicated for the reduction of fever in patients aged 6 months and older, and for the relief of mild-to-moderate pain in patients aged 12